New Phase 3 trial: Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older — GC Biopharma Corp

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-20 12:00 UTC

KINDCompany

DIRECTION■ Mixed

SOURCES1

ENTITIES0

STORY SIZESTANDALONE

FIRST SEEN2026-10-20 12:00 UTC

LAST UPDATE2026-10-20 12:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.

FULL DISPATCH

Sponsor: GC Biopharma Corp; Status: Not Yet Recruiting; Conditions: Influenza A, Influenza B, Influenza Vaccination; Interventions: vaccination of GC3114B, Vaccination of Efluelda; Enrollment: 1806 (estimated); First posted: 2026-10-20; NCT: NCT07883928

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

NO ENTITY LINKS AT DISPLAY CONFIDENCE YET.

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-20 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

←INFERENCEfilings generate company commentary
RTX filed 8-K on 2026-10-202026-10-20 00:00 UTC

←INFERENCEfilings generate company commentary
CRM filed 8-K on 2026-10-202026-10-20 00:00 UTC

←INFERENCEfilings generate company commentary
NFLX filed 8-K on 2026-10-202026-10-20 00:00 UTC

←INFERENCEfilings generate company commentary
JPM filed 8-K on 2026-10-202026-10-20 00:00 UTC

←INFERENCEfilings generate company commentary
LLY filed 4 on 2026-10-202026-10-20 00:00 UTC

←INFERENCEfilings generate company commentary
SMCI filed 8-K on 2026-10-202026-10-20 00:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.